APGE Share Price Performance
US$35.39
-4.97 (-12.31%)
Price US$35.39
Share PriceUS$35.39
APGE Community Narratives
There are no narratives available yet.
Recent APGE News & Updates
No updates
Apogee Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.52
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Apogee Therapeutics, Inc. Competitors
About APGE
- Founded
- 2022
- Employees
- 196
- CEO
- WebsiteView website
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading